✦ LIBER ✦

Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3

✍ Scribed by S. Pianko; S. Zeuzem; W.-L. Chuang; G. R. Foster; S. K. Sarin; R. Flisiak; C.-M. Lee; P. Andreone; T. Piratvisuth; S. Shah; A. Sood; J. George; M. Gould; P. Komolmit; S. Thongsawat; T. Tanwandee; J. Rasenack; Y. Li; M. Pang; Y. Yin; G. Feutren; I. M. Jacobson; for the B2202 Study Team

Book ID: 117947764
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 309 KB
Volume: 19
Category: Article
ISSN: 1352-0504
DOI: 10.1111/j.1365-2893.2012.01586.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety and Antiviral Activity of Albinte

Safety and Antiviral Activity of Albinterferon Alfa-2b Dosed Every Four Weeks in Genotype 2/3 Chronic Hepatitis C Patients

✍ Bain, Vincent G.; Kaita, Kelly D.; Marotta, Paul; Yoshida, Eric M.; Swain, Mark 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 300 KB

Albinterferon alfa-2b dosed every two or

Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C

✍ Stefan Zeuzem; Eric M. Yoshida; Yves Benhamou; Stephen Pianko; Vincent G. Bain; 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 528 KB

The efficacy and safety of albinterferon alfa-2b (alb-IFN), a novel recombinant protein consisting of interferon alfa-2b genetically fused to human albumin, was evaluated in a phase 2b, open-label study of patients with genotype 1, chronic hepatitis C. In all, 458 IFN-alfa treatment-naı ¨ve patients

Albinterferon Alfa-2b Was Not Inferior t

Albinterferon Alfa-2b Was Not Inferior to Pegylated Interferon-α in a Randomized Trial of Patients With Chronic Hepatitis C Virus Genotype 2 or 3

✍ David R. Nelson; Yves Benhamou; Wan–Long Chuang; Eric J. Lawitz; Maribel Rodrigu 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 981 KB

252 Randomized controlled trial of PEGin

252 Randomized controlled trial of PEGinterferon alfa-2A plus ribavirin for chronic hepatitis C virus-genotype 4 among Egyptian patients

✍ Fouad I.A. Thakeb; Mahmoud M. Omar; Mostafa M.E.I. Awady; Sherif Y. Isshak 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 147 KB

424 RESPIRATORY ALTERATIONS IN GENOTYPE

424 RESPIRATORY ALTERATIONS IN GENOTYPE 2/3 CHRONIC HEPATITIS C PATIENTS TREATED WITH PEGYLATED INTERFERON OR ALBINTERFERON-ALFA-2B PLUS RIBAVIRIN IN A RANDOMIZED STUDY

✍ G. Foster; R. Flisiak; W.-L. Chuang; J. George; J. Rasenack; A. Sood; P. Komolmi 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 120 KB

Peginterferon alfa-2b plus ribavirin for

Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial

✍ Savino Bruno; Calogero Cammà; Vito Di Marco; Mariagrazia Rumi; Maria Vinci; Mari 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 373 KB